Group 1 - The company announced that its oral small molecule GLP-1 receptor agonist ASC30 for the treatment of type 2 diabetes has completed the first dosing of participants in a 13-week Phase II study in the U.S., with top-line data expected in Q3 2026 [1] - The company recently completed a 13-week Phase II study evaluating ASC30 for obesity treatment, enrolling 125 obese or overweight participants with at least one weight-related comorbidity across multiple centers in the U.S. [2] - At the primary endpoint of the 13-week study, ASC30 doses of 20 mg, 40 mg, and 60 mg achieved statistically significant and clinically meaningful weight reductions of 5.4%, 7.0%, and 7.7% respectively, with a dose-dependent effect observed [2] Group 2 - The overall discontinuation rate due to adverse events in the Phase II study for ASC30 was 4.8%, indicating a favorable safety profile [2] - ASC30 is the first and only small molecule GLP-1 receptor agonist in clinical research that can be administered both orally once daily and via subcutaneous injection once monthly to quarterly, targeting obesity, diabetes, and other metabolic diseases [2] - The company's strategy to expand ASC30's clinical development into the large diabetes treatment market is seen as a logical next step, providing an opportunity to showcase ASC30 as a best-in-class oral therapy option for patients [3]
歌礼制药-B宣布口服小分子GLP-1R激动剂ASC30治疗糖尿病的13周美国II期研究完成首批受试者给药